kisqali
novartis europharm limited - ribociklib sukcinat - neoplazme dojke - antineoplastična sredstva - kisqali je primerna za zdravljenje žensk z hormon receptorjev (hr)‑pozitiven, human epidermalna rast factor receptor 2 (her2)‑negativna lokalno napredno ali metastatskega raka dojke, v kombinaciji z zaviralec aromataze ali fulvestrant kot začetno endokrine temelji na zdravljenje, ali pri ženskah, ki jih prejeli v pred endokrine terapija. v pre‑ ali perimenopausal ženske, endokrini terapija je treba v kombinaciji z luteinising hormon sproščujoči hormon (lhrh) agonist.
bikalutamid synthon 50 mg filmsko obložene tablete
synthon bv - bikalutamid - filmsko obložena tableta - bikalutamid 50 mg / 1 tableta - bikalutamid
fulvestrant teva 250 mg raztopina za injiciranje v napolnjeni injekcijski brizgi
teva b.v. - fulvestrant - raztopina za injiciranje v napolnjeni injekcijski brizgi - fulvestrant 250 mg / 1 brizga - fulvestrant
fulvestrant lek 250 mg raztopina za injiciranje v napolnjeni injekcijski brizgi
lek d.d. - fulvestrant - raztopina za injiciranje v napolnjeni injekcijski brizgi - fulvestrant 250 mg / 1 brizga - fulvestrant
fulvestrant lek 250 mg raztopina za injiciranje v napolnjeni injekcijski brizgi
lek d.d. - fulvestrant - raztopina za injiciranje v napolnjeni injekcijski brizgi - fulvestrant 250 mg / 1 brizga - fulvestrant
faslodex
astrazeneca ab - fulvestrant - neoplazme dojke - endokrini terapije, anti-estrogene - faslodex is indicated , as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:, , not previously treated with endocrine therapy, or, with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy. , , , in combination with palbociclib for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. v pre - ali perimenopausal ženske, kombinacija zdravljenja z palbociclib je treba v kombinaciji z luteinizirajoči hormon sproščujoči hormon (lhrh) agonist.
ibrance
pfizer europe ma eeig - palbociclib - neoplazme dojke - antineoplastična sredstva - ibrance je primerna za zdravljenje hormonsko receptorjev (hr) pozitiven, human epidermalna rast factor receptor 2 (her2) negativne lokalno napredno ali metastatski rak dojk:v kombinaciji z zaviralec aromataze;v kombinaciji z fulvestrant pri ženskah, ki jih prejeli v pred endokrine terapija. v pre - ali perimenopausal ženske, endokrini terapija je treba v kombinaciji z luteinizirajoči hormon sproščujoči hormon (lhrh) agonist.
fulvestrant mylan
mylan pharmaceuticals limited - fulvestrant - neoplazme dojke - endokrini terapija - fulvestrant je primerna za zdravljenje estrogen receptor pozitivno, lokalno napredno ali metastatskega raka dojke pri ženskah po menopavzi:ne prej, zdravljenih z endokrinih terapije, orwith ponovitve bolezni na ali po adjuvant anti-estrogen terapije, ali napredovanja bolezni na antiestrogen terapija.
verzenios
eli lilly nederland b.v. - abemaciclib - neoplazme dojke - antineoplastična sredstva - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.
fulvestrant aptapharma 250 mg raztopina za injiciranje v napolnjeni injekcijski brizgi
fulvestrant - raztopina za injiciranje v napolnjeni injekcijski brizgi - fulvestrant 250 mg / 1 brizga - fulvestrant